Tigecycline: A first in class glycylcycline

Clinical Microbiology Newsletter

Volumn 26, Issue 21, 2004, Pages 163-168

  Bradford, Patricia A ^a,b  

^a WYETH RESEARCH   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCYLCYCLINE DERIVATIVE; MINOCYCLINE; TIGECYCLINE;

ABDOMINAL INFECTION; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; REVIEW; RIBOSOME; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 7544231416     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2004.10.001     Document Type: Article

References (26)

1. National Nosocomial Infections Surveillance (NNIS) System Report. Am. J. Infect. Control. 31:2003;481-498
2. Streit J.M., et al. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int. J. Antimicrob. Agents. 24:2004;111-118
3. Petersen P.J., et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:1999;738-744
4. Petersen, P.J. et al. 1998. The post-antibiotic effect and time kill kinetics of the glycylcyclines, GAR-936 (TBG-MINO) and PAM-MINO. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy.
5. Hoellman D.B., et al. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 44:2000;1085-1088
6. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A5, 6th ed. NCCLS, Wayne, PA.
7. Kenny G.E, Cartwright F.D. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines and quinolones. Antimicrob. Agents Chemother. 45:2001;2604-2608
8. Roblin P.M., Hammerschlag M.R. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int. J. Antimicrob. Agents. 16:2000;61-63
9. Wallace R.J. Jr., et al. Com- parison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. 46:2002;3164-3167
10. Data on file at Wyeth Pharmaceuticals.
11. Jones R.N. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. Diagn. Microbiol. Infect. Dis. 35:1999;249-252
12. 2+ cleavage of 16S rRNA. J. Antimicrob. Chemother. 53:2004;592-599
13. Brodersen D.E., et al. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell. 103:2000;1143-1154
14. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents: approved guideline M26-A. NCCLS, Wayne, PA.
15. Petersen P.J., et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide- intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob. Agents Chemother. 46:2002;2595-2601
16. Nannini E.C., et al. Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model. Antimicrob. Agents Chemother. 4:2003;529-532
17. Edelstein P.H., Weiss W.J., Edelstein M.A. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 47:2003;533-540
18. Murphy T.M., et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob. Agents Chemother. 44:2000;3022-3027
19. Lefort A., et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 47:2003;216-222
20. van Ogtrop M.L., et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 44:2003;943-949
21. Muralidharan G., et al. Pharmacokinetics (PK), safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother. 39:1999;303
22. Sesoko S., Umemura K., Nakashima M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males (abstract no. A-1403). Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother. 42:2002;22
23. Troy S.M., et al. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. 43:2003;5
24. Zhanel G.G., et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs. 64:2004;63-88
25. Postier R.G., et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin. Ther. 26:2004;704-714
26. Murray J., et al. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients. A phase 2 clinical trial. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. 2003;43-416